Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients

Clinical Pharmacokinetics

Volumn 50, Issue 7, 2011, Pages 451-459

  Glowacki, Franois ^a,b   Lionet, Arnaud ^b   Hammelin, Jean Philippe ^b   Labalette, Myriam ^b   Provt, Franois ^b   Hazzan, Marc ^b   Broly, Franck ^a   Nol, Christian ^b   Cauffiez, Christelle ^a  

^a France Institut Pasteur de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cytochrome P450; Genetic polymorphism; Immunosuppressants; Renal transplant; Switch therapy; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 79958256682     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11587050-000000000-00000     Document Type: Article

References (26)

1. Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007 Jul; 8 (7): 835-49. (Pubitemid 47288980)
2. Jose M. Caring for Australians with Renal Impairment (CARI). The CARI guidelines: calcineurin inhibitors in renal transplantation. Adverse effects. Nephrology (Carlton) 2007 Feb; 12 Suppl. 1: S66-74.
3. Coates PT. Caring for Australians with Renal Impairment (CARI). The CARI guidelines: nephrotoxicity and calcineurin inhibitors. Nephrology (Carlton) 2007 Feb; 12 Suppl. 1: S85-7.
4. Tsuchiya N, Satoh S, TadaH, et al. Influence of CYP3A5 andMDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004 Oct; 78 (8): 1182-7. (Pubitemid 39426437)
5. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines froman experimental study.AmJTransplant 2006Nov; 6 (11): 2706-13. (Pubitemid 44571691)
6. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for onceversus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505-13.
7. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010 Oct; 49 (10): 683-92.
8. de Jonge H, Kuypers DR, Verbeke K, et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel oncedaily tacrolimus formulation. Transplantation 2010 Sep; 90 (5): 523-9.
9. WehlandM, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011 Apr; 21 (4): 179-84.
10. Wallemacq P, Goffinet JS, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott Architect tacrolimus assay. Ther Drug Monit 2009 Apr; 31 (2): 198-204.
11. Thervet E, Loriot AM, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010 Jun; 87 (6): 721-6.
12. Haufroid V, Mourad M, van Kerckhove V, et al. The effects of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004 Mar; 14 (3): 147-54. (Pubitemid 38373108)
13. MacPhee IAM, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics; the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in Whites and South Asians. Transplantation 2005 Feb; 79 (4): 499-502. (Pubitemid 40280186)
14. Hesselink DA, van Schaik RHN, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008 Apr; 18 (4): 339-48. (Pubitemid 351367527)
15. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010 Mar; 49 (3): 141-75.
16. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37 (2): 867-70.
17. Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit 2010 Apr; 32 (2): 129-35.
18. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit 2009 Apr; 31 (2): 139-52.
19. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008; 5 Suppl. 7: S19-24. (Pubitemid 351522770)
20. Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008 Apr; 30 (2): 143-50. (Pubitemid 351521640)
21. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993 Mar; 268 (9): 6077-80. (Pubitemid 23099291)
22. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010 Apr; 49 (4): 207-21.
23. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997 Sep; 27 (2-3): 201-14. (Pubitemid 27417873)
24. Wang D, Johnson A, Papp A, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005 Oct; 15 (10): 693-704. (Pubitemid 41345321)
25. Op den Buijsch RAM, Christiaans MHL, Stolk LML, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphatebinding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007 Aug; 21 (4): 427-35.
26. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009 Nov; 20 (11): 2468-80